International investigation of breast MRI: results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions

Heywang‐Köbrunner, Sylvia H.; Bick, Ulrich; Bradley, William G.; Boné, B.; Casselman, Jan; Coulthard, Alan; Fischer, Uwe; Müller-Schimpfle, Markus; Oellinger, H.; Patt, Richard H.; Teubner, J.; Friedrich, M.; Newstead, Gillian M.; Holland, R.; Schauer, A.; Sickles, Edward A.; Tabár, L.; Waisman, Jerry; Wernecke, KD

doi:10.1007/s003300000745

Cited by 153 publications

(89 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They observed delayed inflow ICG into the malignant breast lesions compared with benign lesions and non-diseased glandular tissue. This observation contradicts our results obtained with fast optical measurement and also the faster inflow of Gd-DTPA into malignant breast lesions on MRI [87].…”

Section: Indocyanine Green As a Fluorescence Contrast Agentcontrasting

confidence: 99%

“…It is known from breast MRI that analysis of early contrast medium dynamics can provide crucial information for the differentiation between malignant and benign breast lesions [85][86][87]: malignant breast lesions tend to enhance much faster than benign lesions within the first minute of contrast medium administration. In optical mammography, analysis of early and very early contrast enhancement is of interest for the following reasons: 1) Despite ongoing technical developments in MR imaging, the temporal resolution achieved is still lower than that of optical techniques [88,89].…”

Section: Indocyanine Green As An Contrast Agent To Enhance Absorptionmentioning

confidence: 99%

See 1 more Smart Citation

Near‐infrared imaging of breast cancer using optical contrast agents

Poellinger

2012

Journal of Biophotonics

View full text Add to dashboard Cite

Breast cancer is the most common malignancy in women worldwide and the second leading cause of cancer death. On the basis of three studies performed by our group, this article reviews the current status of optical breast imaging using extrinsic contrast agents. To date, only two contrast agents have been applied in human studies, indocyanine green (ICG) and omocianine. Both contrast media were used for absorption and fluorescence imaging. Generally speaking, malignant breast lesions exhibited higher absorption contrast as well as higher fluorescence contrast compared to benign lesions or non‐diseased breast tissue. Some groups consider early enhancement characteristics helpful for differentiation between malignant and benign lesions. Late fluorescence ICG imaging – capitalizing on the extravasation of the dye through the wall of tumorous vessels – seems to be a promising technique to distinguish malignant from benign breast lesions. (© 2012 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim)

show abstract

Section: Indocyanine Green As a Fluorescence Contrast Agentcontrasting

confidence: 99%

Section: Indocyanine Green As An Contrast Agent To Enhance Absorptionmentioning

confidence: 99%

Near‐infrared imaging of breast cancer using optical contrast agents

Poellinger

2012

Journal of Biophotonics

View full text Add to dashboard Cite

show abstract

“…Contrast-enhanced magnetic resonance imaging (MRI) has been shown to have a high sensitivity (86% to 100%) for detecting breast cancer in high-risk asymptomatic and symptomatic women, although reports of specificity have been more variable (37% to 97%). [23][24][25][26][27] The American Cancer Society now recommends MRI screening in addition to mammograms for women who meet at least one of the following conditions 28 :…”

Section: Screening Strategies In High-risk Womenmentioning

confidence: 99%

Women at High Risk for Breast Cancer--What the Primary Care Provider Needs to Know

Afonso¹

2009

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

Until recently, the assessment made by the primary care provider regarding screening for breast cancer was generally limited to decisions about when to initiate mammography. Early diagnosis was stressed as the best protection against breast cancer morbidity. However, there have been recent developments in the ability to predict and modify breast cancer risk. It is therefore important for the primary care provider to be able to identify women at higher risk for breast cancer and be familiar with issues regarding screening and risk reduction. Recent data regarding the evaluation of breast cancer risk, newer screening strategies for high-risk women, and medical and surgical approaches to reduce breast cancer risk and are discussed in this article. Each year 170,000 women are diagnosed with breast cancer; screening for breast cancer is one of the topics that primary care providers should address with their patients. Screening for breast cancer has been extensively endorsed and most women in the United States more than 40 years old participate in screening activities.1,2 In the community mammography remains the main screening tool.3 However, there have been several important developments in the ability to predict and modify breast cancer risk. Recently, data have become available regarding the evaluation of risk, screening strategies for high-risk women, and medical and surgical approaches that can decrease breast cancer risk. Women who are concerned about their risk for breast cancer and should be counseled and managed appropriately; it is important for primary care providers to be familiar with these issues. Evaluation of Breast Cancer Risk Average RiskThe National Cancer Institute's Surveillance, Epidemiology, and End Results program estimates that, based on breast cancer statistics from 2001 through 2003, 12.7% of women born in the United States today will develop breast cancer sometime during their lifetime. This average risk of approximately 12% is often expressed as "1 in 8," whereas the chance that a woman will never have breast cancer is 87.3%, or "7 in 8" women. 4Identification of Women at Higher Risk for Breast Cancer Several approaches are available for identifying women with a higher than average risk of breast cancer. These include an assessment of family history with genetic testing consideration; a review of clinical history, including prior breast biopsies; and the evaluation of mammographic density. Family HistoryMany women will have a family history of breast cancer but, among the majority of these women, the risk does not increase substantially and is associated with, at the most, a doubling of the lifetime risk. Only 1% to 2% of breast cancer cases are caused by the inheritance of an autosomal dominant, high-penetrance gene, conferring up to an 85% lifetime risk of breast cancer. In some families, there is also a high risk of ovarian cancer. Features of the family history that suggest cancer may be caused by such a high-penetrance gene include: [5][6][7][8] • Two or more first-degree (parent, sib...

show abstract

“…70 However, specificity has generally been lower and more variable and ranges from 37% to 97%. 3 In a study based on 519 histopathologically correlated lesions, Heywang-Köbrunner and colleagues 71 illustrate the relatively high sensitivity and relatively low specificity of MRI of the breast. Although the multicenter study was aimed at improving standardization of imaging parameters and interpretation guidelines, the elegant design of the study demonstrated the relatively low specificity of MRI of the breast and the tradeoff between specificity and sensitivity.…”

Section: Sensitivity and Specificitymentioning

confidence: 99%